SC US (TTGP), LTD.

SC US (TTGP), LTD. has filed 114 Form 4 transactions across three companies, with a clear buy-side bias. The total value of open-market purchases reached $61.77 million, while open-market sales totaled $9.43 million. That is a ratio of roughly six to one in favor of buying. The entity has not reported any acquired shares through grants or awards, meaning its accumulation has come from direct purchases rather than compensation. The recent activity tells a different story. On August 20, 2026, SC US (TTGP) filed five open-market sales in LIFE, the ticker for aLife Biomedical, with values ranging from $74,130.55 to $1,243,200.13. The combined sale value for that single day was approximately $2.93 million. No open-market purchases have been reported in the most recent period. The subsequent filings on August 21 and September 8, 2026, all carry codes J and C, which are conversions of derivative securities and other non-cash adjustments. Those transactions have a reported value of zero, so they do not change the cash picture. The pattern is straightforward. Over the full filing history, SC US (TTGP) has been a net accumulator, putting far more cash into positions than it has taken out. But the most recent filings show the entity moving in the opposite direction, selling LIFE shares on the open market and then converting derivative positions without adding new cash exposure. The August 20 sales are the only open-market transactions in the recent window, and they are all sells. Whether this marks a shift in the entity's longer-term approach is not something the filings can answer, but the direction of the latest cash transactions is unambiguous.